1282516-69-1

Basic information

• Product Name: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-
• Synonyms: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-;9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine;9-Bromo-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine
• CAS NO: 1282516-69-1
• Molecular Formula: C₁₁H₈BrIN₂O
• Molecular Weight: 391.00249
• Mol File: 1282516-69-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 491.2±55.0 °C(Predicted)
• Appearance: /
• Density: 2.21±0.1 g/cm3(Predicted)
• PKA: 3.32±0.20(Predicted)
• CAS DataBase Reference: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(1282516-69-1)
• EPA Substance Registry System: IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo-(1282516-69-1)

Safety Data

• Hazardous Substances Data: 1282516-69-1(Hazardous Substances Data)

Usage

General Description

IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo- is a complex chemical compound with a fused ring structure containing an imidazole and benzoxazepine ring system. It is further substituted with a bromine atom at the 9-position and an iodo group at the 2-position. IMidazo[1,2-d][1,4]benzoxazepine,9-broMo-5,6-dihydro-2-iodo- is a heterocyclic organic molecule that has potential applications in medicinal chemistry and drug development due to its unique structure and reactivity. It may be used as a precursor or intermediate in the synthesis of pharmaceutical compounds or as a tool compound in chemical and biological research. Proper handling and storage of this chemical are necessary due to its potential reactivity and toxicity.

Upstream product

• 22532-62-3 4-bromosalicylaldehyde 

Downstream Products

• 1282516-74-8 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d]-[1,4]oxazepine-2-carboxylic acid 
• 1401303-65-8 8-bromo-2-pyridin-2-yl-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene 
• 1401300-81-9 2-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)benzenesulfonamide 
• 1282512-48-4 taselisib 
• 2060571-02-8 (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide 

Relevant articles and documents

INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

An inhibitor containing a tricyclic derivative, a preparation method therefor and a pharmaceutical composition comprising the inhibitor, as well as a use thereof as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer and diseases or conditions mediated by or dependent on PI3K imbalance.

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 1: Early-Stage Development Routes to the Bromobenzoxazepine Core

Two convergent regioselective routes for the synthesis of the tetracyclic imidazobenzoxazepine triazole 1, a key intermediate toward the synthesis of taselisib, are described. In the first-generation route, a chemoselective Negishi cross-coupling reaction was developed between iodoimidazole 3 and triazole 7, which enabled the delivery of initial kilogram quantities of 1. Because of the inefficiencies in the preparation of the imidazole 3, a second-generation route via a highly regioselective imidazole ring formation between α-chloroketone 11 and aryl amidine 12 was developed. The resulting imidazole 14 provided the handle to efficiently install the seven-membered benzoxazepine ring system in one pot with two-step N-alkylation and SNAr tandem reactions.

BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.